These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 488666)

  • 21. [The effect of etofibrate on serum cholesterol and triglycerides (author's transl)].
    Dimroth H
    Med Klin; 1979 Jun; 74(22):875-6. PubMed ID: 470785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bile acid metabolism in hyperlipoproteinaemia.
    Hellström K; Einarsson K
    Clin Gastroenterol; 1977 Jan; 6(1):103-28. PubMed ID: 196796
    [No Abstract]   [Full Text] [Related]  

  • 23. Biliary lipid composition during treatment with different hypolipidaemic drugs.
    Angelin B; Einarsson K; Leijd B
    Eur J Clin Invest; 1979 Jun; 9(3):185-90. PubMed ID: 113218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiating of lipid-lowering activity of clofibrate by combining with low doses of 3-pyridylcarbinol in rats.
    Simane Z; Nowak H
    Atherosclerosis; 1974; 20(3):447-52. PubMed ID: 4429617
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of clofibrate on the handling of dietary and liver fat.
    Westerfeld WW; Elwood JC; Richert DA
    Biochem Pharmacol; 1972 Apr; 21(8):1117-25. PubMed ID: 5034197
    [No Abstract]   [Full Text] [Related]  

  • 26. [Field study on the decrease of lipids using etofibrate].
    Schneider J; Haase W; Kaffarnik H
    Fortschr Med; 1976 May; 94(13):785-90. PubMed ID: 8362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The spontaneously hyperlipidemic old rat as a model for evaluation of hypolipoproteinemic drugs. Effects of nicotinic acid, clofibrate and ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate on plasma lipoproteins.
    Gustafsson K; Kiessling H
    Z Versuchstierkd; 1982; 24(5-6):262-70. PubMed ID: 7170838
    [No Abstract]   [Full Text] [Related]  

  • 28. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L; Olsson AG; Rössner S; Carlson LA
    Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of nicotinic acid on catabolism and synthesis of cholesterol in man.
    Miettinen TA
    Clin Chim Acta; 1968 Apr; 20(1):43-51. PubMed ID: 5652004
    [No Abstract]   [Full Text] [Related]  

  • 30. Changes produced by clofibrate in hepatocytes of rats with sucrose-induced hyperlipidemia.
    Kim J; Goldfischer S; Biempica L
    Exp Mol Pathol; 1976 Dec; 25(3):263-78. PubMed ID: 187444
    [No Abstract]   [Full Text] [Related]  

  • 31. Management of the hyperlipidemic patient.
    Berkowitz D
    Med Clin North Am; 1973 Jul; 57(4):881-92. PubMed ID: 4576152
    [No Abstract]   [Full Text] [Related]  

  • 32. Results of treatment of hyperlipidemias: long-term compliance and effect of lipid metabolism.
    Frantz ID
    Adv Exp Med Biol; 1977; 82():649-55. PubMed ID: 920422
    [No Abstract]   [Full Text] [Related]  

  • 33. Stimulation of anti-aggregatory activity from rat aorta by hypolipidemic drugs.
    Weithmann KU; Granzer E
    Artery; 1980; 8(5):475-81. PubMed ID: 7011266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Etofibrate and clofibrate in double blind study].
    Rahlfs VW; Zimmermann H; Safer A
    Dtsch Med Wochenschr; 1976 Jul; 101(31):1168-9. PubMed ID: 789039
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of various hypolipidemic drugs on fatty acid composition of liver and serum lipids.
    Maier R; Muller K
    Adv Exp Med Biol; 1975; 63():349-57. PubMed ID: 1199873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of action of hypolipidemic drugs.
    Sirtori CR; Torreggiani D; Fumagalli R
    Adv Exp Med Biol; 1975; 63():123-33. PubMed ID: 1106138
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
    Petit D; Bonnefis MT; Rey C; Infante R
    Atherosclerosis; 1988 Dec; 74(3):215-25. PubMed ID: 3240333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The lipid-reducing efficiency of a clofibrate-inositolnicotinate combination in comparison with clofibrate. The wrong use of statistical methods--presented on an example from clinical research].
    Haase W; Kluthe R; Schäfer B
    Med Welt; 1975 Nov; 26(47):2157-9. PubMed ID: 1105056
    [No Abstract]   [Full Text] [Related]  

  • 39. [The experimental effect of amino acids on lipid metabolic indices].
    Chistiakova AM; Miroshkina VN; Ryzhenkov VE
    Vopr Pitan; 1990; (1):40-4. PubMed ID: 2346010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The common hyperlipoproteinemias: an understanding of disease mechanisms and their control.
    Fisher WR; Truitt DH
    Ann Intern Med; 1976 Oct; 85(4):497-508. PubMed ID: 184730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.